明德生物
(002932)
| 流通市值：31.22亿 | | | 总市值：46.50亿 |
| 流通股本：1.56亿 | | | 总股本：2.33亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,366,471,800.49 | 2,179,486,275.19 | 3,196,431,442.74 | 2,555,555,115.35 |
| 应收票据及应收账款 | 1,608,185,686.99 | 2,183,216,809.02 | 2,470,731,048.27 | 2,669,513,201.98 |
| 其中：应收票据 | 43,661,193.2 | 20,730,000 | 47,398,199.07 | 109,932,554.15 |
| 应收账款 | 1,564,524,493.79 | 2,162,486,809.02 | 2,423,332,849.2 | 2,559,580,647.83 |
| 应收款项融资 | 48,582,650.4 | 10,001,203.2 | 77,256,483.38 | 66,973,127.77 |
| 预付款项 | 67,439,236.94 | 66,020,516.11 | 72,316,220.42 | 56,621,767.7 |
| 其他应收款合计 | 88,929,186.55 | 19,008,747.22 | 56,178,164.59 | 14,690,542.07 |
| 存货 | 104,798,606.15 | 123,829,961.26 | 225,618,938.36 | 258,435,444.29 |
| 一年内到期的非流动资产 | - | - | - | 70,000,000 |
| 其他流动资产 | 180,860,610.57 | 213,909,351.67 | 201,761,636.98 | 37,299,184.64 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 4,530,267,778.09 | 4,850,472,863.67 | 7,353,054,345.7 | 7,681,848,794.76 |
| 非流动资产: | | | | |
| 长期股权投资 | 48,229,587.3 | 48,229,587.29 | 48,842,942.63 | 47,092,942.63 |
| 其他权益工具投资 | 160,500,000 | 70,000,000 | 36,400,000 | 36,400,000 |
| 固定资产 | 387,045,911.97 | 392,834,493.15 | 372,627,096.13 | 367,288,093.29 |
| 在建工程 | 164,121,893.76 | 142,210,983.57 | 137,218,566.98 | 121,517,787.39 |
| 使用权资产 | 25,572,494.45 | 29,959,339.99 | 34,033,680.72 | 37,163,203.86 |
| 无形资产 | 17,908,809.91 | 17,356,881.65 | 16,884,941.79 | 16,861,755.69 |
| 长期待摊费用 | 22,703,000.51 | 19,651,869.92 | 16,017,511.45 | 17,205,466.54 |
| 递延所得税资产 | 158,934,228.87 | 166,605,912.18 | 172,348,503.03 | 170,242,620.75 |
| 其他非流动资产 | 2,194,295,238.88 | 2,238,605,240.1 | 682,723,449.35 | 695,327,760.81 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,179,311,165.65 | 3,125,454,307.85 | 1,517,096,692.08 | 1,509,099,630.96 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 7,709,578,943.74 | 7,975,927,171.52 | 8,870,151,037.78 | 9,190,948,425.72 |
| 流动负债: | | | | |
| 短期借款 | 138,549,608.1 | 190,014,107.5 | 180,014,107.5 | 164,668,276 |
| 应付票据及应付账款 | 757,965,288.76 | 939,512,681.24 | 1,219,278,752.2 | 1,293,854,856.16 |
| 其中：应付票据 | 239,796,825.42 | 130,000,000 | - | - |
| 应付账款 | 518,168,463.34 | 809,512,681.24 | 1,219,278,752.2 | 1,293,854,856.16 |
| 合同负债 | 62,646,224.03 | 117,345,009.68 | 140,181,780.76 | 309,578,503.81 |
| 应付职工薪酬 | 247,918,410.38 | 252,267,046.33 | 296,352,289.6 | 352,698,351.66 |
| 应交税费 | 9,310,660.38 | 14,770,211.2 | 22,692,853.15 | 165,141,051.02 |
| 其他应付款合计 | 36,297,381.44 | 30,862,430.98 | 67,575,846.58 | 46,365,714.49 |
| 一年内到期的非流动负债 | 262,890.81 | 13,963,420.27 | 13,227,262.54 | 18,174,042.14 |
| 其他流动负债 | 2,463,415.38 | 15,234,097.87 | 5,894,597.61 | 14,456,678.06 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,255,413,879.28 | 1,573,969,005.07 | 1,945,217,489.94 | 2,364,937,473.34 |
| 非流动负债: | | | | |
| 租赁负债 | 30,295,247.95 | 21,042,150.93 | 25,951,973.22 | 20,752,095.62 |
| 递延收益 | 5,960,000 | 5,960,000 | 5,960,000 | 5,960,000 |
| 递延所得税负债 | 27,460,334.59 | 27,460,334.59 | 27,460,334.59 | 27,460,334.59 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 63,715,582.54 | 54,462,485.52 | 59,372,307.81 | 54,172,430.21 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,319,129,461.82 | 1,628,431,490.59 | 2,004,589,797.75 | 2,419,109,903.55 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 232,520,957 | 232,520,957 | 156,193,021 | 156,193,021 |
| 资本公积 | 820,417,750.84 | 818,125,402.14 | 891,560,855.48 | 887,893,835.9 |
| 减:库存股 | 15,243,951.08 | 15,243,951.08 | 16,018,488 | 16,018,488 |
| 盈余公积 | 607,378,740.38 | 607,378,740.38 | 607,378,740.38 | 607,378,740.38 |
| 未分配利润 | 4,435,997,071.05 | 4,403,398,017.51 | 4,947,393,213.27 | 4,864,504,382.25 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 6,081,070,568.19 | 6,046,179,165.95 | 6,586,507,342.13 | 6,499,951,491.53 |
| 少数股东权益 | 309,378,913.73 | 301,316,514.98 | 279,053,897.9 | 271,887,030.64 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 6,390,449,481.92 | 6,347,495,680.93 | 6,865,561,240.03 | 6,771,838,522.17 |
| 负债和股东权益合计 | 7,709,578,943.74 | 7,975,927,171.52 | 8,870,151,037.78 | 9,190,948,425.72 |
| 公告日期 | 2023-10-31 | 2023-08-31 | 2023-04-27 | 2023-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |